Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. - Wikidata - awgldk - TriplyDB

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

http://www.wikidata.org/entity/Q35232352

about

Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis Promising biological therapies for ulcerative colitis: A review of the literature New Immunosuppressive Therapies in Uveitis Treatment Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases Golimumab for the treatment of ulcerative colitis TNF inhibitor therapy for rheumatoid arthritis Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.New treatments for ulcerative colitis: do we have pediatric data?Golimumab for the treatment of ulcerative colitis.Have we overestimated the benefit of human(ized) antibodies?Detection and characterization of subvisible aggregates of monoclonal IgG in serum Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study.Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.Multivalent pIX phage display selects for distinct and improved antibody properties.Golimumab pharmacokinetics in ulcerative colitis: a literature review Recent advances in managing and understanding uveitis.TNF inhibition for ophthalmic indications: current status and outlook.Investigational cytokine-targeted therapies for ulcerative colitis.Targeting TNF-α for the treatment of inflammatory bowel disease.Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.Vedolizumab for the treatment of ulcerative colitis.Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists.Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.Necroinflammation in Kidney Disease.New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease.The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.Golimumab for treatment of axial spondyloarthritis.

P2860

Q26764801-3D74FA99-1E58-490F-B75F-35096E0F337C Q26776139-7B3F2E9E-4756-47B1-99EC-5ADD76C1CFE4 Q26798201-DD6BB306-D8E6-4802-846B-AF05201C60B3 Q26849811-B6C3644C-5695-41FA-B466-ABC73D699053 Q26999078-C674EBCB-6762-4DD2-A4AF-C8855A096330 Q28067245-FC723EA4-3FAF-4587-8579-7F8C8C537680 Q28236322-70E92EA7-EF0A-4A15-9EBA-E9B1B3E1F2B4 Q28972424-6CE3F789-3ABD-4F7F-821E-189ACA268C24 Q30240229-5540A04B-E178-4E31-BCD9-01EF0E1F4D2C Q31076366-0D0A37B9-E737-40CE-BEBB-010E4FF4789E Q33852257-B10D5282-005B-4EE8-B071-118DC0D78220 Q34142714-155716F2-AA6D-4DB8-8109-D6578BD9A893 Q34216430-136519AE-BB22-4F69-B22F-AC7FC2DC766E Q35544546-49D070DF-F465-462A-82AE-8036075637A8 Q35569418-498B60C4-2254-409E-9CCD-6865E87F8522 Q36023494-CA7F946E-CF2B-45D4-8C20-F2FF26AD641D Q36085461-11E2F91C-D251-4586-BB33-8C5D6B9A4349 Q36767782-82A083F0-29DE-49BC-9B43-82AC9A19D806 Q37130039-F6A84C79-24E9-4DB6-9965-33DD85560BB0 Q37267600-72265804-7CA7-4E6F-A05D-77CB1FDB5781 Q37501464-9F53CDC4-814B-458A-8FE8-5C4587A9ACFC Q37671983-70430B52-8799-42C4-98C4-77A2715668F3 Q37709700-CB191270-08AB-4D5D-A6B6-8E7550B9D9F4 Q38097327-45F3ECB8-D7C4-4430-922C-1E51D6C5C62A Q38117175-967CD7E4-5FAF-4928-B2B2-D11F5A933562 Q38160905-527F2314-793C-4129-81EB-A668B23B2FE7 Q38201788-2DFD74D4-8F31-4E06-8D0E-C374E7D7F3AA Q38209809-806161D1-B847-463C-96C5-966B4352AC81 Q38239111-CD3E53A0-8DAF-419B-99EA-1D49C8183986 Q38364465-2D04A100-9BFA-4E7E-AB1A-587D7FAC94BB Q38365049-E9C9202C-511B-48E9-A4DC-110E02C48748 Q38365426-BA0E27CB-88BD-4669-9381-AD5A9013922D Q38579499-6C9C1424-A053-4C70-A945-9CBB20C1576E Q38582765-D9489F85-AE1A-4083-B998-67210321900B Q38591244-C657BC02-961E-4CD4-B03C-20761F1F5CCF Q38591272-0FFCE003-2D79-429F-8862-C2887F40F86B Q38592363-5905AD1B-1133-4756-B3B0-DE9562CCCCCE Q38645738-099E6EB5-91B9-4ACE-8175-D8BEDBDB3CC9 Q38652276-DA014BC8-13E7-4A23-BD7D-9EEE7FAAEAB0 Q38707718-ECEFAEF8-4007-4682-8E8D-2F811FD819C9

P2860

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

http://www.wikidata.org/entity/Q35232352

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Characterization of golimumab, ...... human tumor necrosis factor α.

@ast

Characterization of golimumab, ...... human tumor necrosis factor α.

@en

type

label

Characterization of golimumab, ...... human tumor necrosis factor α.

@ast

Characterization of golimumab, ...... human tumor necrosis factor α.

@en

prefLabel

Characterization of golimumab, ...... human tumor necrosis factor α.

@ast

Characterization of golimumab, ...... human tumor necrosis factor α.

@en

P1433

Q35232352-FC67227C-EE1F-4D79-A4CB-990356C1133D

P1476

Q35232352-00ADD21D-2515-493A-9500-728DD0C16CA6

P2093

Q35232352-04A0CBCB-159A-43C7-9325-3BD7E4712A09

Q35232352-0602CEE6-C453-4205-90F0-95375666013E

Q35232352-145256B5-8C63-4B17-A19C-4DF722B75ACB

Q35232352-334E9662-F1AA-42DE-B32F-FD1996F79D6F

Q35232352-4A7E391B-57E5-4A71-A40F-1E4D3678D3A1

Q35232352-4D9D25C0-C1FA-4DA8-8F29-5CE0AB276D10

Q35232352-5707EA0F-52E7-4A7A-A129-B171F9BD0E07

Q35232352-596B2C8E-EB8B-49BE-87D1-4480E17CEA8C

Q35232352-6A9419A9-03DA-49A7-8E17-572737F2C848

Q35232352-7F3DA719-890F-45DD-8411-DE4B7E94EF31

P2860

Q35232352-0F6552AC-6068-4D2D-B196-020362872A64

Q35232352-16166810-8DD1-4F07-90BE-0C5D39979F3E

Q35232352-250D0F18-8915-4046-9D67-3147CA2D139F

Q35232352-2B2B4DAD-22CE-450B-A5BD-0FC23DCE63B7

Q35232352-2D57FD69-BDC2-430B-B507-02BD14B981EF

Q35232352-356D84C1-83CB-43BF-AD03-4784D42FDDB3

Q35232352-361BA64A-B364-481C-8AB1-D6F3091E6457

Q35232352-3AAB4F8B-1A31-4473-BBEE-D3FC9A9D4330

Q35232352-430655AC-B980-4276-808C-9CB53C4D03C3

Q35232352-45D186E8-A1C2-4B96-9DF6-43D21D0FD3C8

P304

Q35232352-49EFA203-6EEE-427C-82A6-B32CCFCEAB4D

P31

Q35232352-D4E6A5AB-E3C7-4849-9F6B-685C881FD783

P356

Q35232352-E81BDEEA-2789-4A77-B7CF-BDB5DDDCF840

P433

Q35232352-15D38C5D-2FE2-4498-91B3-DF03DFBE8383

P478

Q35232352-D867D4B4-F8C9-4AFF-99D3-27E24EFC97B9

P577

Q35232352-4863CCAB-7566-4145-83AE-C53D5D02CF5B

P5875

Q35232352-4D73FC04-E674-441A-955E-80C9B5F70925

P698

Q35232352-27A04549-4E68-4C20-80EB-BAA058C934CA

P921

Q35232352-B24F48EA-2D0E-4E88-B73F-30FC5BEE8A9A

P932

Q35232352-68828843-E384-4DAA-9637-23BAFC68A426

P356

P1433

Monoclonal Antibodies

P1476

Characterization of golimumab, ...... human tumor necrosis factor α.

@en

P2093

Ann Cai

http://www.w3.org/2001/XMLSchema#string

Audrey Baker

http://www.w3.org/2001/XMLSchema#string

Bernard J Scallon

http://www.w3.org/2001/XMLSchema#string

Bill Pikounis

http://www.w3.org/2001/XMLSchema#string

Dana Wang

http://www.w3.org/2001/XMLSchema#string

David J Shealy

http://www.w3.org/2001/XMLSchema#string

Eilyn R Lacy

http://www.w3.org/2001/XMLSchema#string

Eva Emmell

http://www.w3.org/2001/XMLSchema#string

George Gunn

http://www.w3.org/2001/XMLSchema#string

Honghui Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols

Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice

Fully human antibodies from transgenic mouse and phage display platforms.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Inflammation in autoimmunity: receptors for IgG revisited.

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

IMGT-ONTOLOGY and IMGT databases, tools and Web resources for immunogenetics and immunoinformatics.

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.

P304

428-439

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.12304

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44646539

http://www.w3.org/2001/XMLSchema#string

P698

20519961

http://www.w3.org/2001/XMLSchema#string

P921

P932

3180089

http://www.w3.org/2001/XMLSchema#string